Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Duvelisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD known ✓ | O00329 | 19/20 | 0.76 |
| ▸ | PIK3CG known ✓ | P48736 | 12/20 | 0.76 |
| ▸ | PIK3R1 | P27986 | 13/20 | 0.76 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.76 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.76 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.76 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | HTR2A | P28223 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Duvelisib SCHEMBL12688631 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| Duvelisib SCHEMBL31628293 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| Duvelisib SCHEMBL153544 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| Duvelisib SCHEMBL29538168 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| Duvelisib SCHEMBL153543 | 1.00 | PIK3CD (0.76) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL12688592 | 0.95 | PIK3CD (0.69) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL12688231 | 0.94 | PIK3CD (0.68) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL12688709 | 0.93 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL12688232 | 0.93 | PIK3CD (0.67) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL12688591 | 0.92 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| CN-105682658-B | Cancer therapy using PI3 kinase subtype modulators | 无限药品公司 | 2022-04-05 | — | — | CN | claimed |
| WO-2025188783-A9 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-119632992-A | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024263804-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING KIDNEY CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263801-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING OVARIAN CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| CN-114401723-B | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2024-11-08 | — | — | CN | disclosed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-116850288-A | Medicine for treating Du Weili Sibutus intestinal toxicity by taking CK1 epsilon gene or protein as target point | 浙江大学智能创新药物研究院 | 2023-10-10 | — | — | CN | disclosed |
| CN-111675710-B | Preparation method of duloxetine | 上海奥萝拉医药科技有限公司 | 2023-08-18 | — | — | CN | disclosed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | disclosed |
| EP-4054601-A1 | METHODS OF MAKING CELLULAR THERAPIES | Secura Bio, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-3474856-B1 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-108699061-B | Deuterated compounds for the treatment of hematological malignancies, inflammation, and autoimmune diseases | 纽弗姆制药有限公司 | 2022-07-05 | — | — | CN | disclosed |
| EP-3999065-A1 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING CANCERS | Pattern Computer, Inc. (US) | 2022-05-25 | — | — | EP | disclosed |
| CN-114401723-A | Therapeutic compositions and methods for treating cancer | 帕特恩电脑公司 | 2022-04-26 | — | — | CN | disclosed |